See more : Rashtriya Chemicals and Fertilizers Limited (RCF.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Oncotelic Therapeutics, Inc. (OTLC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncotelic Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Xilinx, Inc. (0M1U.L) Income Statement Analysis – Financial Results
- Swisscom AG (0QKI.L) Income Statement Analysis – Financial Results
- Netac Technology Co., Ltd. (300042.SZ) Income Statement Analysis – Financial Results
- Bubalus Resources Limited (BUS.AX) Income Statement Analysis – Financial Results
- Sun Rise E&T Corporation (1343.TWO) Income Statement Analysis – Financial Results
Oncotelic Therapeutics, Inc. (OTLC)
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.00K | 0.00 | 0.00 | 1.74M | 0.00 | -100.00 | -100.00 | 0.00 | 0.00 | 95.00K | 95.00K | 156.00K | 0.00 | 0.00 | 0.00 | 12.00K | 12.00K | 0.00 | 1.00K | 7.00K | 30.00K | 334.52K | 9.86M | 1.69M | 1.27M | 100.00K | 100.00K | 100.00K | 100.00K | 300.00K | 100.00K | 100.00K |
| Cost of Revenue | 0.00 | 12.84K | 61.51K | 0.00 | 60.60K | 34.19K | 9.00K | 19.00K | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.94M | 22.27M | 17.92M | 13.05M | 10.48M | 0.00 | 0.00 | 1.51M | 1.61M | 1.26M | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 70.00K | -12.84K | -61.51K | 1.74M | -60.60K | -34.29K | -9.10K | -19.00K | -20.00K | 95.00K | 95.00K | 156.00K | 0.00 | 0.00 | 0.00 | -25.93M | -22.26M | -17.92M | -13.05M | -10.47M | 30.00K | 334.52K | 8.35M | 79.97K | 16.27K | 200.00K | 100.00K | 100.00K | 100.00K | 300.00K | 100.00K | 100.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 34,289.00% | 9,100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | -216,066.67% | -185,508.33% | 0.00% | -1,304,700.00% | -149,614.29% | 100.00% | 100.00% | 84.70% | 4.72% | 1.28% | 200.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 61.14K | 756.91K | 3.66M | 4.30M | 1.37M | 815.00K | 10.47M | 8.76M | 9.09M | 7.41M | 3.64M | 3.52M | 5.29M | 12.11M | 22.26M | 18.43M | 14.13M | 10.82M | 7.10M | 5.85M | 3.94M | 5.10M | 6.13M | 8.06M | 8.40M | 10.40M | 7.30M | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 573.73K | 4.85M | 5.47M | 5.02M | 2.94M | 2.19M | 3.37M | 5.00M | 4.60M | 5.24M | 4.74M | 4.69M | 5.38M | 5.89M | 8.90M | 7.52M | 8.16M | 7.10M | 5.95M | 4.54M | 5.28M | 7.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.43B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 573.73K | 4.85M | 5.47M | 5.02M | 2.94M | 2.19M | 3.37M | 5.00M | 4.60M | 5.24M | 4.74M | 4.69M | 5.38M | 5.89M | 8.90M | 7.52M | 8.16M | 7.10M | 5.95M | 4.54M | 5.28M | 7.44M | 5.45M | 3.16M | 3.34M | 3.10M | 3.00M | 1.80M | 4.10M | 3.10M | 2.10M | 1.60M |
| Other Expenses | 6.08M | 533.49K | 0.00 | 0.00 | 0.00 | -1.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 98.00K | 98.00K | 97.54K | 297.54K | -230.83K | 35.00K | 100.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.72M | 5.61M | 9.13M | 9.33M | 4.31M | 3.00M | 13.84M | 13.76M | 13.68M | 12.65M | 8.38M | 8.21M | 10.67M | 18.00M | 31.16M | 25.95M | 22.29M | 17.92M | 13.05M | 10.49M | 9.32M | 12.64M | 11.88M | 10.99M | 11.77M | 13.60M | 10.40M | 6.60M | 4.10M | 3.10M | 2.10M | 1.60M |
| Cost & Expenses | 6.72M | 5.61M | 9.13M | 9.33M | 4.31M | 3.00M | 13.84M | 13.76M | 13.68M | 12.65M | 8.38M | 8.21M | 10.67M | 18.00M | 31.16M | 25.95M | 22.29M | 17.92M | 13.05M | 10.49M | 9.32M | 12.64M | 13.39M | 12.60M | 13.02M | 13.50M | 10.40M | 6.60M | 4.10M | 3.10M | 2.10M | 1.60M |
| Interest Income | 0.00 | 2.97K | 2.00K | 2.00K | 123.00 | 16.00K | 35.00K | 106.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 618.00K | 1.96M | 0.00 | 0.00 | 0.00 | 0.00 | 334.52K | 906.89K | 1.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.04M | 2.97M | 2.00M | 2.00M | 749.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K | 52.72K | 61.25K | 102.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -513.26K | 12.84K | 61.51K | 364.21K | 60.60K | 34.19K | 9.00K | 19.00K | 20.00K | 109.00K | 110.00K | 127.00K | 150.00K | 96.00K | 123.00K | 231.00K | 213.00K | 186.00K | 142.00K | 125.00K | 576.00K | 243.11K | -7.13M | -230.83K | 35.00K | 100.00K | 100.00K | 500.00K | 300.00K | 0.00 | 0.00 | -100.00K |
| EBITDA | -7.16M | -5.60M | -9.06M | -7.61M | -4.25M | -678.55K | -13.80M | -13.64M | -13.63M | -12.54M | -8.17M | -7.95M | -9.50M | -23.58M | -28.72M | -21.69M | -20.18M | -15.27M | -11.77M | -9.90M | -8.71M | -12.06M | -3.23M | -11.14M | -11.72M | -13.43M | -10.25M | -6.50M | -4.00M | -2.80M | -2.00M | -1.50M |
| EBITDA Ratio | -10,230.39% | 0.00% | 0.00% | -414.77% | 0.00% | 3,250,000.00% | 13,833,000.00% | 0.00% | 0.00% | -13,318.95% | -8,718.95% | -5,150.64% | 0.00% | 0.00% | 0.00% | -242,583.33% | -183,241.67% | 0.00% | -1,404,500.00% | -154,442.86% | -32,226.67% | -4,007.35% | -27.13% | -657.14% | -921.28% | -15,300.00% | -12,400.00% | -7,200.00% | -4,400.00% | -933.33% | -2,000.00% | -1,500.00% |
| Operating Income | -6.65M | -9.72M | -9.13M | -7.58M | -4.31M | -3.00M | -13.84M | -13.76M | -13.68M | -12.65M | -8.28M | -8.07M | -11.89M | -18.51M | -31.16M | -25.94M | -22.27M | -17.92M | -13.05M | -10.48M | -9.29M | -12.30M | -3.53M | -10.91M | -11.75M | -13.40M | -10.30M | -6.50M | -4.00M | -2.80M | -2.00M | -1.50M |
| Operating Income Ratio | -9,497.16% | 0.00% | 0.00% | -435.69% | 0.00% | 3,002,000.00% | 13,842,000.00% | 0.00% | 0.00% | -13,315.79% | -8,715.79% | -5,174.36% | 0.00% | 0.00% | 0.00% | -216,166.67% | -185,608.33% | 0.00% | -1,304,800.00% | -149,714.29% | -30,960.00% | -3,678.28% | -35.75% | -643.52% | -924.04% | -13,400.00% | -10,300.00% | -6,500.00% | -4,000.00% | -933.33% | -2,000.00% | -1,500.00% |
| Total Other Income/Expenses | -1.56M | 14.40M | -1.39M | -2.39M | -2.33M | 0.00 | 30.00K | 105.00K | 28.00K | 3.00K | 3.00K | -7.00K | 2.24M | -5.26M | 2.21M | 4.02M | 1.88M | 1.98M | 1.14M | 456.00K | 920.00K | 0.00 | -552.31K | 0.00 | 0.00 | 2.09M | 2.23M | 700.00K | 400.00K | 2.80M | 2.00M | 0.00 |
| Income Before Tax | -8.21M | 4.68M | -10.52M | -9.97M | -6.64M | -2.74M | -13.81M | -13.65M | -13.65M | -12.65M | -8.28M | -8.08M | -10.88M | -24.28M | -28.94M | -22.54M | -22.34M | -15.46M | -11.91M | -10.02M | -8.33M | -10.96M | -4.08M | 0.00 | 0.00 | -11.40M | -8.10M | -5.80M | -3.60M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -11,722.95% | 0.00% | 0.00% | -572.81% | 0.00% | 2,737,000.00% | 13,812,000.00% | 0.00% | 0.00% | -13,312.63% | -8,712.63% | -5,178.85% | 0.00% | 0.00% | 0.00% | -187,825.00% | -186,200.00% | 0.00% | -1,190,900.00% | -143,200.00% | -27,773.33% | -3,276.54% | -41.35% | 0.00% | 0.00% | -11,400.00% | -8,100.00% | -5,800.00% | -3,600.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -13.14M | 876.57K | 1.53M | 749.60K | -265.00K | -30.00K | -105.00K | -28.00K | -3.00K | -3.00K | 22.00K | -2.24M | 5.26M | -6.43M | -4.54M | -1.88M | -2.46M | -1.14M | -456.00K | -920.00K | -1.29M | 613.56K | -1.82M | -1.30M | -1.90M | -2.20M | -500.00K | -300.00K | 2.80M | 2.00M | 100.00K |
| Net Income | -7.90M | 17.82M | -11.39M | -11.50M | -7.39M | -2.74M | -13.81M | -13.65M | -13.65M | -12.65M | -8.28M | -8.08M | -9.65M | -23.77M | -24.73M | -21.40M | -20.39M | -15.46M | -11.91M | -10.02M | -8.37M | -11.01M | -4.14M | -9.09M | -10.45M | -11.50M | -8.10M | -6.00M | -3.70M | -2.80M | -2.00M | -1.60M |
| Net Income Ratio | -11,290.13% | 0.00% | 0.00% | -660.65% | 0.00% | 2,737,000.00% | 13,812,000.00% | 0.00% | 0.00% | -13,312.63% | -8,712.63% | -5,178.85% | 0.00% | 0.00% | 0.00% | -178,341.67% | -169,908.33% | 0.00% | -1,190,900.00% | -143,200.00% | -27,893.33% | -3,292.30% | -41.97% | -536.15% | -821.50% | -11,500.00% | -8,100.00% | -6,000.00% | -3,700.00% | -933.33% | -2,000.00% | -1,600.00% |
| EPS | -0.02 | 0.05 | -0.04 | -0.13 | -0.12 | -0.07 | -0.52 | -0.51 | -0.54 | -0.75 | -2.95 | -5.48 | -10.37 | -71.60 | -111.11 | -167.56 | -175.20 | -134.28 | -145.35 | -145.28 | -152.33 | -211.22 | -88.04 | -195.06 | -244.09 | -271.28 | -198.94 | -193.56 | -151.20 | -134.40 | -120.00 | -108.00 |
| EPS Diluted | -0.02 | 0.04 | -0.04 | -0.13 | -0.12 | -0.07 | -0.52 | -0.51 | -0.54 | -0.75 | -2.95 | -5.48 | -10.37 | -71.60 | -111.11 | -167.56 | -175.20 | -134.28 | -145.35 | -145.28 | -152.33 | -211.22 | -88.04 | -195.06 | -244.09 | -271.28 | -198.94 | -193.56 | -151.20 | -134.40 | -120.00 | -108.00 |
| Weighted Avg Shares Out | 396.17M | 384.08M | 303.08M | 88.10M | 59.96M | 37.25M | 26.55M | 26.55M | 25.20M | 16.97M | 2.80M | 1.47M | 931.00K | 332.00K | 222.56K | 127.72K | 116.38K | 115.11K | 81.93K | 69.00K | 54.93K | 52.14K | 47.01K | 46.59K | 42.81K | 42.39K | 40.72K | 31.00K | 24.47K | 20.83K | 16.67K | 14.82K |
| Weighted Avg Shares Out (Dil) | 396.17M | 457.30M | 303.08M | 88.10M | 59.96M | 37.25M | 26.55M | 26.55M | 25.20M | 16.97M | 2.80M | 1.47M | 931.00K | 332.00K | 222.56K | 127.72K | 116.38K | 115.11K | 81.93K | 69.00K | 54.93K | 52.14K | 47.01K | 46.59K | 42.81K | 42.39K | 40.72K | 31.00K | 24.47K | 20.83K | 16.67K | 14.82K |
Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.
AGOURA HILLS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its Chief Executive Officer (“CEO”), Dr. Vuong Trieu, will be a featured speaker at the upcoming Ibero-American Chatbot...
Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results
AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced financial results for the...
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023
AGOURA HILLS, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today it was featured in Life Sciences Review, Cancer Immunology Edition and has been awarded a Top Cancer Immunotherapy...
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer
AGOURA HILLS, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its joint venture partner, GMP Biotechnology Limited's wholly owned subsidiary – Sapu Bioscience, LLC (“Sapu”), together with with...
Oncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual Meeting 2022
AGOURA HILLS, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) ( OTCQB:OTLC ), a leading developer of TGF-β therapeutics for oncology and virology, today announced that it will present new studies on...
Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference
AGOURA HILLS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” ) ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that Dr....
Source: https://incomestatements.info
Category: Stock Reports